Phase II evaluation of mitoxantrone in advanced non anaplastic thyroid cancer

Sixteen evaluable patients with non anaplastic thyroid carcinoma were treated with mitoxantrone (16 mg/m2). There was only one brief partial remission (6.3%). There was noticeable toxicity. Mitoxantrone as given in this study was not effective for this patient population.